Benjamin Jackson CFA, an analyst from Jefferies, maintained the Buy rating on Galderma Group AG (GALD – Research Report). The associated price target remains the same with CHF112.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Benjamin Jackson CFA has given his Buy rating due to a combination of factors that highlight Galderma Group AG’s strong market performance and potential for future growth. The US sales volumes for Galderma’s product, Nemluvio, have consistently exceeded expectations, with a notable 5% week-over-week growth. This robust volume growth aligns with the firm’s optimistic projections, reinforcing confidence in the company’s market position.
Moreover, the average number of prescriptions, which count for two pens, is significantly higher than anticipated, suggesting strong demand and effective market penetration. While there remains some uncertainty regarding net pricing evolution, the current sales trajectory suggests that Galderma is well-positioned to maintain a competitive edge. These positive indicators contribute to the Buy rating, as they suggest a promising outlook for Galderma’s financial performance in the near future.